Found 167 clinical trials
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary efficacy of
- 0 views
- 18 Dec, 2021
- 1 location
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which
- 0 views
- 22 Dec, 2021
- 1 location
Trial Of Pembrolizumab And Nintedanib (PEMBIB)
these two approaches is tolerable. Moreover, comprehensive pre-clinical and clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy for the benefit of the patients
- 0 views
- 27 Jan, 2022
- 1 location
A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer
hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or
- 0 views
- 10 Oct, 2022
- 2 locations
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN)
growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), basic fibroblast growth factor (BFGF), and transforming growth factor (TGF)-α and -β. The (over
- 0 views
- 24 Mar, 2022
- 14 locations
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (ICEMELT)
(5) PD1/L1 inhibitor and vascular endothelial growth factor (VEGF) inhibitor.
- 0 views
- 23 Mar, 2022
- 2 locations
A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
% to 75%, and is the main cause of reoperation. Anti-Vascular endothelial growth factor (VEGF) therapy for vitreous hemorrhage can inhibit neovascularization and prevent recurrent vitreous haemorrhage
- 0 views
- 04 Oct, 2022
- 1 location
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma
development of Advanced Biliary Tract Carcinoma (BTC) and chronic inflammation is a common underlying risk factor for BTC. Vascular endothelial growth factor (VEGF) signaling in BTC may lead to an immune
- 12 views
- 04 Oct, 2022
- 1 location
Temporal Relations and Exercise Interventions of Various Gait and Cognitive Domains in Older Adults
endothelial growth factor (VEGF) and expression of the apolipoprotein E (APOE) ε4 allele parallel changes in gait characteristics and cognitive functions after the intervention will be examined.
- 0 views
- 11 Oct, 2022
- 1 location
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
PDR, which were the collection of vascular endothelial growth factor (VEGF) factors and the major component of proliferative lesion in the later stage of PDR. Micro-invasive Pars-plana
- 0 views
- 06 Apr, 2023
- 1 location